12/17
12:53 pm
ptgx
Rating for PTGX
Low
Report
Rating for PTGX
12/17
12:53 pm
ptgx
Rating for PTGX
Low
Report
Rating for PTGX
12/17
07:19 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/8
02:42 pm
ptgx
Rating for PTGX
Low
Report
Rating for PTGX
12/8
02:42 pm
ptgx
Rating for PTGX
Low
Report
Rating for PTGX
12/8
07:22 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
11/10
04:55 pm
ptgx
Rating for PTGX
Low
Report
Rating for PTGX
11/10
04:55 pm
ptgx
Rating for PTGX
Low
Report
Rating for PTGX
11/7
03:08 pm
ptgx
Rating for PTGX
Low
Report
Rating for PTGX
11/7
10:46 am
ptgx
Rating for PTGX
Low
Report
Rating for PTGX
11/7
10:46 am
ptgx
Rating for PTGX
Low
Report
Rating for PTGX
10/28
09:10 am
ptgx
Rating for PTGX
Medium
Report
Rating for PTGX
10/28
09:10 am
ptgx
Rating for PTGX
Medium
Report
Rating for PTGX
10/28
08:09 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $82.00 price target on the stock.
Medium
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $82.00 price target on the stock.
10/28
05:18 am
ptgx
Rating for PTGX
Medium
Report
Rating for PTGX